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Available online 14 October 2017Immunoglobulin A vasculitis (IgAV), also referred to as Henoch-Schönlein purpura, is the most common form of
childhood vasculitis. The pathogenesis of IgAV is still largely unknown. The disease is characterized by IgA1-
immune deposits, complement factors and neutrophil infiltration, which is accompanied with vascular inflam-
mation. Incidence of IgAV is twice as high during fall and winter, suggesting an environmental trigger associated
to climate. Symptoms can resolve without intervention, but some patients develop glomerulonephritis with fea-
tures similar to IgA nephropathy that include hematuria, proteinuria and IgA deposition in the glomerulus. Ulti-
mately, this can lead to end-stage renal disease. In IgA nephropathy immune complexes containing galactose-
deficient (Gd-)IgA1 are found and thought to play a role in pathogenesis. Although Gd-IgA1 complexes are
also present in patientswith IgAVwith nephritis, their role in IgAV is disputed. Alternatively, it has beenproposed
that in IgAV IgA1 antibodies are generated against endothelial cells. We anticipate that such IgA complexes can
activate neutrophils via the IgA Fc receptor FcαRI (CD89), thereby inducing neutrophil migration and activation,
which ultimately causes tissue damage in IgAV. In this Review, we discuss the putative role of IgA, IgA receptors,
neutrophils and other factors such as infections, genetics and the complement system in the pathogenesis of IgA
vasculitis.
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IgA vasculitis (IgAV), also referred to as Henoch-Schönlein purpura,
is characterized by immunoglobulin A1 (IgA1)-dominant immune de-
posits affecting small vessels, and often involves skin, gastrointestinal
tract, joints, and kidney [1]. IgAV is themost common form of childhood
vasculitis with a reported annual incidence rate of 3–26,7/100.000 [2,3],
although it is likely that the incidence is underestimated due to
underreporting. Ten percent of the total patient population is adult,
with an annual incidence rate of 0,8–1,8/100.000 [2]. A higher incidence
of IgAV is reported in both adolescent and adult males than females [3].
The disease ismost prevalent in South-East Asia and to a lesser extent in
Europe and North-America, but IgAV is rare in Africa [2,4]. Symptoms
include palpable purpura or petechiae, (poly)arthralgia, gastrointestinal
disturbances and glomerulonephritis (Table 1). Cutaneous hemor-
rhages are a prerequisite for diagnosis and are caused by leakage of
red blood cells into the skin ormucousmembranes, possibly by a necro-
tizing vasculitis of small vessels in the dermis. Usually, the symptoms in
the acute stage of disease are self-limiting and resolvewithout interven-
tion. However, in part of the patients glomerulonephritis develops,
which can lead to end-stage renal disease in a small percentage of pedi-
atric patients.
Despite the fact that IgAV has been recognized for over 200 years
and is themost common form of vasculitis, the causal pathogenicmech-
anisms have yet to be resolved. It is important to understand the causal-
ity, as this may lead to prevention of disease or to development of new
therapeutics. Vascular inflammation is accompanied by IgA1 deposits,
complement factors and large neutrophil infiltrates. IgA vasculitis with
nephritis (IgAVN) resembles IgA nephropathy (IgAN). Both diseases
are characterized by hematuria, proteinuria and immune complex de-
position in the glomerularmesangium. However, IgA nephropathy is re-
stricted to the kidneys, and it has been hypothesized that IgAV and
IgAVN may represent systemic equivalents of IgAN [5]. Therefore, it is
interesting to explore if pathogenic mechanisms proposed for IgAN
may also apply for IgAV.
IgA is the main component of the immune deposits in IgA vasculitis.
Its origin and specific target antigen(s) are unknown. Additionally, it is
unclear why IgA complexes are deposited in the vasculature. In the
next sections, several findings regarding the role of IgA in IgA vasculitis
are highlighted, which are summarized in a multi-hit model to explain
the pathogeneses of IgAV and IgAVN. This model differs from the
multi-hit model which describes the pathomechanisms leading to glo-
merulonephritis during IgAVN and IgAN. Furthermore, we anticipateTable 1
Overview of symptoms associated with pediatric IgAV [3].
Symptoms Affected body area
Palpable purpura or petechiae Skin (mainly lower extrem
lower parts of the arm)
(Poly)arthralgia Joints (knees and ankles)
Gastrointestinal disturbances
(incl. hematochezia and colicky abdominal pain)
Lower digestive tract
Glomerulonephritis Kidneythat IgA antibodies activate neutrophils via the IgA receptor FcαRI,
thereby inducing neutrophil migration and activation, with concomi-
tant tissue damage.
2. IgA and IgA receptors
Immunoglobulin A is amember of the human immunoglobulin fam-
ily. It consists of two heavy and two light chains, with Fab regions that
bind antigens and a Fc-tail which can interact with Fc receptors. IgA is
mostly known as the dominant antibody subclass present in mucosal
areas, where it plays a key role in mucosal defense. Mucosal secretory
IgA (SIgA) provides ‘immuneexclusion’ by binding to pathogens in a hy-
drophilic shell conformation, which is repelled from mucosal surfaces.
Additionally, IgA can also neutralize bacterial products, agglutinate mi-
crobes and interfere with bacterial motility [6]. In the blood circulation,
1–3mg/ml IgA is present as amonomericmolecule (mIgA or serum IgA)
[7]. Two isoforms of IgA exist.Within the circulation approximately 90%
of the IgA present is IgA1, whereas b10% is IgA2 [8]. IgA1 has an extend-
ed hinge region due to an insertion of two octapeptide repeats. The re-
peats have 3 to 6 common O-glycan sites to which O-glycans can be
attached during glycosylation.
It has been shown that IgA can activate complement proteins. Com-
plement is present in its inactive form in the circulation, and three path-
ways can lead to the activation of complement. IgA cannot activate the
classical route of complement, since it is lacking a C1q binding site.
However, it has been demonstrated that IgA can induce the mannan-
binding lectin and alternative complement pathways [9,10]. Further-
more, IgA can bind to and activate multiple receptors. One of these is
the transferrin receptor (CD71), which is universally expressed as a
transmembrane glycoprotein. The transferrin receptor is important for
the import of iron in the cell by binding to transferrin-iron complexes.
It is thought that overexpression of this receptor bymesangial cells facil-
itates the deposition of IgA1-containing immune complexes in the
mesangium (see also Section 3.1) [11]. The prototypic IgA receptor is
FcαRI, which can be present as a transmembrane receptor on myeloid
cells and in soluble form (sCD89). The soluble form is generated by
shedding of the extracellular part of FcαRI from themembrane. Soluble
FcαRI can form immune complexes with IgA and is thought to play a
role in IgA nephropathy progression (see also Section 3.1) [12]. FcαRI
is present as transmembrane receptor on several myeloid cell types
and can act as bi-functional receptor. It is able to induce pro-
inflammatory reactions but can also trigger inhibitory signals, a proper-
ty that can be exploited to reduce the susceptibility to autoimmune andAverage duration Estimated % of patients affected
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which contains Immunoreceptor Tyrosine-based Activation Motif
(ITAMs) to propagate downstream signals. Monomeric IgA can bind
to, but not cross-link FcαRI, inducing anti-inflammatory responses.
Monovalent targeting of FcαRI results in the formation of intracellular
structions named ‘inhibisomes’, which hamper signaling of neighboring
activated receptors (like Fc epsilon receptors, Fc gamma receptors or
Toll-like receptors) [13]. This process is termed inhibitory ITAM
(ITAMi) signaling and results in the downregulation of immune activa-
tion [14,15]. In contrast, binding of IgA immune complexes to FcαRI on
neutrophils induces activating ITAM signaling. Cross-linking of FcαRI
results in multiple pro-inflammatory functions, such as phagocytosis,
production of reactive oxygen species (ROS), release of granules con-
taining toxic molecules such as lactoferrin, cytokine and chemokine se-
cretion, antibody-dependent cellular cytotoxicity (ADCC) and the
release of neutrophil extracellular traps (NETs) [16,17]. Furthermore,
FcαRI triggering induces the release of chemoattractant LTB4, resulting
in neutrophil migration [18].
The interaction between IgA and FcαRI has been implicated in sever-
al IgAmediated autoimmune diseases, such as linear IgA bullous disease
(LABD), rheumatoid arthritis (RA) and ulcerative colitis [6,19,20]. These
diseases are characterized by IgA autoantibodies which target self-
antigens such as collagen XVII in LABD and the Fc domain of human
IgG in RA. Since IgA autoantibodies can form complexes and activate
neutrophils via FcαRI, this leads to pro-inflammatory effector functions,
neutrophil recruitment and eventually to tissue destruction. Blocking
the interaction between IgA and FcαRI was shown to reduce tissue
damage in an ex vivo model of LABD [20]. Since both neutrophils and
IgA are present in IgA vasculitis lesions, it is likely that the interaction
between IgA and FcαRI plays a role in the pathogenesis of IgA vasculitis.
3. The role of galactose-deficient IgA1 in IgA vasculitis
3.1. Galactose-deficient IgA1 and immune complexes
In IgAN and IgAVN it has been shown thatO-glycans in the hinge re-
gion of human IgA1 are aberrantly glycosylated [21,22]. Glycosylation is
a post-translationalmodificationwhich involves the addition of glycans,
thereby influencing structure, form and effector functions of immuno-
globulins [23]. It is hypothesized that genetic predisposition and/ormu-
cosal infection and concomitant interleukin (IL)-6 production cause
aberrant glycosylation by altering the glycosylation machinery [24].
IgA1 in IgANand IgAVN is galactose-deficient (Gd-IgA1), thereby expos-
ing subjacent GalNAc-residues, which can function as neoepitopes [21,
22]. Autoantibodies recognizing GalNAc-structures can consequently
form immune complexes by binding to Gd-IgA1 [25–29] (Fig. 1). The or-
igin of these autoantibodies is poorly understood. Possibly, Gd-IgA1 it-
self induces production of anti-Gd-IgA1 autoantibodies, but they canFig. 1.Galactose-deficient IgA in immune complexes. (A) IgA2doesnot have a hinge region,whe
(circle), galactose (square) and sialic acid (polygon). Galactose-deficient IgA1 does not contain
IgA1 and soluble Fc alpha receptor (sCD89).also be cross-reactive antibodies which are previously produced in re-
sponse to GalNAc-containing molecules on pathogens [30,31].
Additionally, it was shown that Gd-IgA1 forms complexes with sol-
uble IgA Fc alpha receptor (sCD89) [32,33] (Fig. 1). This molecule can
be shedded from the membrane of monocytes after activation of
FcαRI [12]. sCD89 entails the extracellular part of the receptor, and is
therefore capable of binding IgA. Serum levels of Gd-IgA1-sCD89 com-
plexes in IgAN patients were found to correlate with disease severity
and progression, but not with disease susceptibility [34]. Additionally,
components in food may contribute to the pathogenesis of IgAN. Glia-
din, a component of gluten, was shown to directly interact with
sCD89, thereby aggravating IgAN development in a mouse model of
IgAN [35]. A gluten-free diet may thus be beneficial for patients with
IgAN.3.2. Mesangial deposition of Gd-IgA1-immune complexes in IgAVN
In IgAVN, Gd-IgA1, autoantibodies and sCD89 form large immune
complexes. Small circulating immune complexes are generally cleared
by hepatocytes in the liver, but it is thought that large immune com-
plexes cannot enter the liver via the Disse space [5,36,37]. This results
in enhanced levels of circulating Gd-IgA1 immune complexes and even-
tual deposition of immune complexes in the glomerulus. Several mole-
cules have been suggested to facilitate binding of Gd-IgA1 immune
complexes to mesangial cells, including extracellular matrix proteins,
integrins and the transferrin receptor CD71 [11,38,39]. In mice, it was
shown that immune complexes containing Gd-IgA1 can bind to trans-
ferrin receptors on mesangial cells (Fig. 2). Subsequently,
transglutaminase 2 (TG2) expression is induced on the mesangial cell
surface, leading to upregulation of transferrin receptor expression [11,
33,40]. Thus, initial binding of immune complexes tomesangial cells re-
sults in a positive feedback loop, resulting in enhanced immune com-
plex deposition. Additionally, these complexes can activate mesangial
cells to produce several cytokines, thereby affecting the glycosylation
machinery and possibly enhancing the formation of Gd-IgA1 [40]. Gd-
IgA1 containing immune complexes from IgAN patients were shown
to stimulatemesangial proliferation and induce production of cytokines
and components of the extracellular matrix. Interestingly, Gd-IgA1
alone does not have these stimulatory effects, thereby highlighting the
crucial role of immune complexes for the induction of nephritis [36,
41–46]. Additionally, the amount of circulating immune complexes
was found to correlate with disease severity and progression [25,47,
48]. Patients with IgAVN have an increased expression of transferrin re-
ceptors on their mesangium [49]. Furthermore, IgG present in immune
complexes may bind to Fc gamma receptors on mesangial cells [50]. In
summary, increased levels of Gd-IgA1-sCD89 complexes, together
with the presence of Gd-IgA1-specific autoantibodies and localreas thehinge region of IgA1 can be glycosylated. Healthy IgA1 is glycosylatedwithGalNAc
galactose in its hinge region. (B) Gd-IgA1 can form immune complexes with IgG anti-Gd-
Fig. 2. The role of Gd-IgA1 in glomerulonephritis. Gd-IgA1 containing immune complexes are formed and circulate in the blood stream (see also Fig. 1). In the kidney, they bind to
Transferrin Receptors (TFR) on mesangial cells. This induces expression of Transglutaminase 2, which leads to increased expression of TFR. Furthermore, binding of immune complexes
induces mesangial cell activation, leading to production of cytokines, extracellular matrix components and proliferation.
1249M.H. Heineke et al. / Autoimmunity Reviews 16 (2017) 1246–1253activation of complement, may lead to inflammation of the glomerulus
and impaired renal function [51].
3.3. The presence of Gd-IgA1 in IgA vasculitis
Although it is generally accepted that Gd-IgA1 plays a role in patho-
genesis of IgAN and IgAVN, its presence and role in IgA vasculitis remain
controversial. Two studies claim the absence of thesemolecules in IgAV
patients, and found no differences in serum Gd-IgA1 levels between
IgAV patients and healthy controls [28,29]. Additionally, immune com-
plexes in sera of patientswith IgAV did not contain IgG,whereas IgG im-
mune complexes were found in IgAVN patients [52]. Possibly, the
presence of IgG in immune complexes facilitates deposition on the glo-
merular mesangium. In conclusion, although immune complexes con-
taining Gd-IgA1 are implicated in glomerulonephritis during IgAN and
IgAVN, it is unknown if Gd-IgA1 plays a role in the pathogenesis of sys-
temic inflammation during IgA vasculitis.
4. The role of anti-endothelial cell antibodies in IgA vasculitis
IgA vasculitis is characterized by IgA1-autoantibodies, but the
(auto)antigen towhich IgA1 binds is unknown. In several other vascular
disorders, including systemic lupus erythematosus and systemic vascu-
litis, anti-endothelial cell antibodies (AECA) have been associated with
disease [53]. AECA are a heterogeneous group of antibodies directed
against poorly characterized antigens on human endothelial cells. IgA
from serum of IgAV patients has been found to bind to human endothe-
lial cells in vitro, supporting the presence of IgA
AECA [54]. It has been hypothesized that microorganisms have sim-
ilar antigenic structures as human vessel walls. Infection with thesemi-
croorganisms could lead to the production of cross-reactive AECA,
although no specific microorganism has been identified in IgAV yet
[54]. A possible candidate antigen is β2-glycoprotein I (β2GPI), as IgA
from IgAV patients boundmore avidly to this specific antigen than con-
trol IgA [55]. β2GPI is a serum molecule that binds to phospholipids on
the endothelial cell surface [56]. Possibly, β2GPI adheres to endothelial
cells and exposes antigens which are normally hidden [55]. Other auto-
antibodies recognizing β2GPI-associated phospholipids have been pre-
viously detected in serum of IgAV patients [57–60]. Interestingly, IgA
AECA from IgAVN patients bound to bovine glomerular endothelial
cells, whereas no binding of serum from IgAV patients was detected
[61]. This suggests that antigen-specificity of AECA between IgAV and
IgAVN patients may differ.It is unclear which role AECA play in pathogenesis. AECA promoted
vascular damage in several animal models by endothelial cell activation
and ADCC or complement dependent cytotoxity (CDC) [62]. It was fur-
thermore shown in vitro that IgA AECA from IgAV patients induced en-
dothelial cells to produce cytokines such as IL-8, thereby promoting an
inflammatory milieu and inducing neutrophil chemotaxis [63,64]. Ele-
vated levels of systemic TNF-α during IgAV [65] might increase inflam-
mation, as TNF-α enhanced binding of AECA to endothelial cells and
induced IL-8 release by endothelial cells [54,64]. Furthermore, IgA
AECA from IgAV patients induced CDC of endothelial cells in vitro [55].
It is unknown via which route complement was activated in these ex-
periments. Additionally, in accordancewith Yang et al. [54], we hypoth-
esize that IgA induces neutrophil activation via FcαRI, resulting in
neutrophil activation and chemotaxis (Fig. 3). Vascular damage is in-
duced by IgA via inflammatory processes including ADCC, ROS produc-
tion and NET formation. Additionally, IgA stimulation of neutrophils
leads to the release of LTB4, inducing subsequent neutrophil migration
in a positive feedback loop [18]. We have observed that FcαRI contrib-
utes to tissue damage in several IgA-mediated diseases, including
LABD and RA [19,20]. Furthermore, in a tumor model, neutrophil
targetingwith IgA antibodies led to TNF-α release, which prompted en-
dothelial cells to produce IL-8 and thereby enhanced neutrophil migra-
tion [66]. In conclusion, anti-endothelial cell antibodies might bind to
autoantigens on endothelial cells, inducing cross-talk between IgA, neu-
trophils and endothelial cells, ultimately leading to neutrophil infiltra-
tion and vascular damage.
5. Additional factors involved in IgAV
5.1. The involvement of complement
The complement system is part of the innate immune systemwhich
can enhance attack or clearance of microbes. Skin and mesangial de-
posits in IgAV and IgAVN contain the complement components C3 and
C5-C9 [5,67]. These components are able to form the membrane attack
complex, which is capable of disrupting the membrane of target cells.
Additionally, C5a is a neutrophil chemoattractant, which possibly en-
hances neutrophil recruitment during systemic inflammation. Further-
more, C3a and C5a increase the secretion of IL-8 by endothelial cells
in vitro [67], thereby further attracting neutrophils. Involvement of
the classical route of activation in IgAV is not likely, since IgA cannot ac-
tivate the classical pathway and the main classical pathway activator
C1q is not present in immune complexes. Several findings imply the
Fig. 3. The hypothesized role of AECA in IgA vasculitis. (1) TNF-α enhances binding of IgA1 AECA to endothelial cells. (2) Endothelial cells produce IL-8, inducing neutrophil migration.
(3) The interaction between IgA1 AECA and FcαRI on neutrophils induces LTB4 release, inducing neutrophil recruitment. (4) Furthermore, the interaction of IgA and FcαRI induces
release of ROS, NETosis and ADCC. (5) This ultimately leads to vascular damage.
1250 M.H. Heineke et al. / Autoimmunity Reviews 16 (2017) 1246–1253alternative pathway of complement activation in IgAVetiology. Analysis
of serum of acute pediatric IgAV patients showed a significant increase
in levels of C3a, C5a and Bbbut not of C4a [67]. Bb is the catalytic subunit
of factor B, which is only involved in the alternative pathway. Further-
more, deletions in genes encoding for proteins that compete with com-
plement factor H, a factor negatively regulating complement in the
alternative pathway, were correlated with decreased susceptibility to
IgAVN and IgAN [68,69]. Recently, the lectin binding pathway of com-
plement activation has been implicated in IgAVN and IgAN as well,
since IgA can activate mannan-binding lectin [9]. Additionally, factors
involved in the lectin binding pathway have been found in glomerular
depositions and serum of IgAN and IgAVN patients [70–72]. Comple-
ment was essential for the development of glomerulonephritis in an
IgAN mouse model [73], but the exact pathomechanisms in IgAVN and
IgAV require further investigation.
5.2. Genetics
Although nomutations have been shown to directly cause IgAV, sev-
eral factors implicate genetic factors in pathogenesis of IgAV. First, IgAV
incidence differs between ethnic groups, with highest incidence in
South-East Asians and low incidence in African people [2]. In a study
performed in England, African American children were four times less
likely to develop IgAV, compared to children from Caucasian and
Indian ancestry [4]. Second, although familial aggregation of IgAV is
rare, several cases have been reported [74]. When comparing genetic
variants between healthy and IgAV patients, the biggest difference
was found in HLA genes. Variants HLA-DRB1*01 and HLA-DRB1*11
were associatedwith IgAV, whereas HLA-DRB1*07was negatively asso-
ciated with IgAV [75]. Irrespective of HLA-DRB1 status, HLA-B*41:02
was found to be a susceptibility marker for IgAV development [76].
HLA genes code for MHC molecules, which are important for antigen
presentation to T cells. The involvement of HLA genes could indicate
that antigen presentation and T cell activation are important in control-
ling autoimmune diseases [77]. Other genes involved in cytokine and
chemokineproduction, the renin-angiotensin system, complement acti-
vation, and endothelium activity regulation have also been implicated
in IgAV susceptibility [78–80].
5.3. Infections
Since IgA vasculitis regularly appears after bacterial or viral infec-
tions during the fall season, it is hypothesized that infections play a
role in the etiology of IgAV. Possibly, GalNAc on the surface of pathogens
may facilitate the production of cross-reactive IgA and IgG, which recog-
nizeGd-IgA1 [30]. Alternatively,microorganisms could harbor antigenic
structures resembling those of vessel walls, inducing the development
of cross-reactive autoantibodies [54]. Additionally, mucosal infectionleads to upregulation of IL-6, which could lead to development of Gd-
IgA1 by altering the glycosylationmachinery [24]. There is no particular
infectious pathogen known to cause IgAV, although Helicobacter pylori
has been associated with disease. IgAV patients with H. pylori infection
improved after pathogen eradication, while recurrence of disease was
associated with H. pylori recolonization [81]. Additionally, H. pylori-
positive children had a 3.8 times higher chance to develop IgAV com-
pared to uninfected children [82]. Interestingly, H. pylori-specific anti-
bodies bound to affected renal tissue of IgAVN patients, possibly by
binding to immune complexes or to renal tissue directly [83]. Further-
more, a virulence factor of H. pyloriwas shown to promote the produc-
tion of Gd-IgA1, as it downregulated enzymes involved in
galactosylation [84]. Other possible pathogenic microorganisms have
been extensively reviewed in [78]. Interestingly, several bacteria, in-
cluding S. pneumonia and H. influenza, secrete IgA1 proteases, which
are capable of cleaving the hinge of IgA1 [85]. IgA1 proteases could
also cleave Gd-IgA1, implying that these molecules could be used as
therapeutic tool for IgA1-mediated diseases [86]. Indeed, it was shown
that IgA1 proteases could be used to treat or prevent IgAN in vitro and
in vivo [86–88].
6. Two models to explain pathogenesis of vasculitis and
glomerulonephritis
6.1. Multi-hit model for glomerulonephritis in IgAN and IgAVN
Recently a multi-hit hypothesis for IgA nephropathy has been pro-
posed by Novak et al. [22,36]. The first hit comprises the increased
level of circulating Gd-IgA1, influenced by both environmental and ge-
netic factors (Fig. 4A). Second, antibodies recognizing Gd-IgA1 are pro-
duced or already present, possibly attributable to molecular mimicry.
The formation of Gd-IgA1-containing immune complexes is thirdly me-
diated by complement factors and IgA receptors such as CD71 and
sCD89. Fourth, Gd-IgA1-containing immune complexes deposit in the
mesangium, hereby inducing activation of human mesangial cells,
which ultimately leads to renal dysfunction [22,36]. Although the
model explains the renal symptoms as described for IgAN and IgAVN,
it is unclear if Gd-IgA1 antibodies also play a role in the development
of IgAV.
6.2. Multi-hit model for vasculitis in IgAV and IgAVN
Alternatively, we propose a multi-hit hypothesis to explain the sys-
temic symptoms of IgAV and IgAVN. This novelmodel, (partly) based on
thework of Chiang et al. [54,55,63,64], includes the interaction between
IgA and FcαRI, resulting in neutrophil activation and recruitment. Here,
the first hit is the increased serum level of IgA1 AECA, possibly influ-
enced by genetics or molecular mimicry (Fig. 4B). This is followed by
Fig. 4.Multi-hit pathogenesis model for (A) glomerulonephritis in IgAN and IgAVN and (B) vasculitis in IgAV and IgAVN.
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to β2GPI on endothelial cells. Third, the binding of AECA to human en-
dothelial cells induces the production of IL-8, which is a potent
chemoattractant for neutrophils. Lastly, the attracted neutrophils
become activated by the interaction between IgA1 and FcαRI. Processes
such asADCC, CDC, NETosis and ROSproduction cause damage of vascu-
lar endothelial cells. Furthermore, IgA-activated neutrophils release
LTB4, thereby attracting and activating other neutrophils in a positive
feedback loop. Additionally, neutrophils release TNF-α, which is
thought to further activate endothelial cells and induces endothelial
cells to expose antigens which are normally hidden. AECA antibodies
recognizing these antigens can subsequently bind to endothelial anti-
gens. The activation of neutrophils ultimately leads to inflammation
and vascular hemorrhaging as observed in IgAV and IgAVN.
7. Open questions and future research
Many open questions remain to be answered to fully understand IgA
vasculitis (Table 2). Several factors complicate research into IgA vascu-
litis. First, since it is generally a self-limiting disease, minimal funding
is devoted to unravel the underlying pathomechanisms. Second, it is dif-
ficult to obtain patient material in large sample sizes, since patients are
often not hospitalized and disease course is usually benign. Third, since
the classification of IgA vasculitis includes renal symptoms, data on IgAV
patients often involves IgAVN patients as well. It is important to make a
distinction between IgAV with and without glomerulonephritis to un-
derstand the differences in etiology between systemic and renal symp-
toms. Fourth, although multiple animal models for IgA nephropathy
exist [36], literature on IgAV animal models is scarce. Rat and rabbitTable 2
Open questions regarding the pathogenesis of IgAV.
What is the form and origin of IgA1 in IgAV?
Are there immune complexes present in IgAV?
Is IgA1 in IgAV galactose-deficient?
To which antigen is IgA1 directed?
Do AECAs play a role in IgAV?
Why do some IgAV patients develop IgAVN?
Are IgAV, IgAVN and IgAN entities of the same disease?
Which role does complement play in etiology?
Does a genetic mutation or infectious agent trigger disease?
Are there differences in pathogenesis between pediatric and adult IgAV patients?models developed for IgA vasculitis are induced by injecting the antigen
ovalbumin and thereby inducing an allergic reaction [89–91]. It is un-
known if these models are representative to study the
pathomechanisms of IgAV. Additionally, most experimental animal spe-
cies do not express FcαRI, which omits the effects of neutrophil activa-
tion via FcαRI. Therefore, model systems including humanized FcαRI
are highly desired and necessary to fully understand pathogenesis of
IgAV.
8. Conclusion
It has been hypothesized that IgAV, IgAVN and IgAN are all entities of
the same disease. The two multi-hit hypotheses proposed here suggest
that renal and systemic symptoms during IgAV, IgAVN and IgAN may
have different origins (Fig. 4). IgAN is marked by the presence of Gd-
IgA1, resulting in the formation of immune complexes, whereas IgA1
possibly recognizes endothelial cell antigens in IgAV. IgAVN could be
viewed as a dual disease, in which both components of IgAV and IgAN
are interwoven. Other factors, such as genetics, infection and comple-
ment also play a role in pathogenesis. Based on previous observations
regarding the pathogenic role of the IgA Fc receptor FcαRI in LABD
and RA, we anticipate that FcαRI plays an important role in etiology of
IgA vasculitis by inducing neutrophil migration and activation. The
unraveling of the exact pathomechanisms of IgAV will provide direc-
tions for prevention of disease, identification of biomarkers and future
therapeutics.
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